LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Chemed Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

May 20, 2024 | Last Trade: US$443.49 1.45 0.33

CINCINNATI / May 20, 2024 / Business Wire / Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2024 annual stockholders’ meeting.

Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company’s independent accountants for 2024. Stockholders also approved Chemed’s executive compensation. In addition, stockholders voted against the stockholder proposal on ratification of termination pay.

Dividend Declared

Following the stockholders’ meeting, Chemed’s Board of Directors declared a quarterly cash dividend of 40 cents per share on the Company’s capital stock, payable on June 18, 2024, to stockholders of record as of May 30, 2024. This represents the 212th consecutive quarterly dividend paid to stockholders in Chemed’s 53 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care, and Roto-­Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page